Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
about
Subtype-specific therapy for autoimmune neuropathies?Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy.Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.Severe refractory CIDP: a case series of 10 patients treated with bortezomib.Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.Novel Therapeutic Avenues for Chronic Inflammatory Demyelinating Polyneuropathy: The Difficulties of Disease Diversity.Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins.Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy.Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components.Neurofascin-155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment.Unconventional treatments for chronic inflammatory demyelinating polyneuropathy.Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy.Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases.A New Classification System for IgG4 Autoantibodies.Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.Head and voice tremor improving with immunotherapy in an anti-NF155 positive CIDP patient.Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance.The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.Diagnostic insights into chronic-inflammatory demyelinating polyneuropathiesDetection Methods for Autoantibodies in Suspected Autoimmune Encephalitis
P2860
Q36092674-39CA63DF-0A1D-40DD-BDC4-7379C8629254Q38711142-47319C47-5B9D-4752-8CFE-25E0688C78B5Q38748481-2D8568F3-A958-48D1-A3A7-98308F3051E1Q39434973-DCB4CA78-9553-4F42-9E77-E585B0F5BA3AQ40081746-651457CB-7A4E-432C-A1C7-2CD5699E415EQ40097140-B40B990A-82DF-4ACD-A28F-BDB4775A779FQ41002811-D3684FBC-658D-41D0-8990-A4923D50B9D0Q41253790-715BDCEC-8DF4-4721-B8DA-FAD905D6C601Q43533051-00D67FFC-108A-4604-B586-290B37FEB82FQ46866734-670C0FD7-0677-48B1-99F0-21891B4FDDD1Q47327481-83D60A18-A4AE-4753-BBE1-307BE2F8129FQ47610103-E4F86384-A5DC-4150-AAEB-4BFFEC06F8DEQ47611455-57068059-5365-429A-9051-55D1445A8D27Q48013653-00177130-EE53-4E7E-B48A-63BB0CABAC82Q48033560-D9BFAEF5-3AA5-4ACC-8F78-6CC75ABD0972Q48301410-1479D808-D8EC-4D83-97F7-951C38C01D8BQ48366711-E2D64FBA-7632-412B-9900-7C96685AB9C7Q50327901-01F4CDB4-B33C-40AA-A8FC-DF5CC2BA1089Q53174125-35F12243-142E-4B1C-86BD-8163AA32916FQ53647790-FF7B8EDC-A291-48F6-A8B2-66CD773251CFQ53821750-AD28CC3A-EF8C-4D12-AEEC-7CFC580C0BC9Q55021064-8214E08C-00BD-42F4-B0CF-E021A28810ADQ55228908-B609B3F3-4F5D-467D-93A0-330AC8B9389AQ57300562-1A999C3D-B455-4035-AE7D-8A67C7E94DF6Q58576008-223E6302-FC25-4421-B168-4FE817798623
P2860
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
@en
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
@nl
type
label
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
@en
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
@nl
prefLabel
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
@en
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
@nl
P2093
P2860
P50
P1476
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins
@en
P2093
Alejandra Carvajal
Angel Ortega-Moreno
Isabel Illa
Laia Seró-Ballesteros
Luis Querol
Maria Jose Sedano
Nicolau Ortiz
P2860
P356
10.1212/NXI.0000000000000149
P577
2015-09-03T00:00:00Z